Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project

authors

• Beau-Faller Michèle
• Pencreach Erwan
• Leduc Charlotte
• Blons Hélène
• Merlio Jean-Philippe
• Bringuier Pierre-Paul
• de Fraipont Florence
• Escande Fabienne
• Lemoine Antoinette
• Ouafik L'Houcine
• Denis Marc
• Hofman Paul
• Lacave Roger
• Melaabi Samia
• Langlais Alexandra
• Missy Pascale
• Morin Franck
• Moro-Sibilot Denis
• Barlesi Fabrice
• Cadranel Jacques

keywords

• Variant allele frequency VAF
• T790M
• Non-small cell lung cancer NSCLC
• Droplet digital PCR ddPCR
• EGFR mutation

abstract

T790M mutations inEGFR-mutated non-small cell lung cancer (NSCLC) account for nearly 50% of acquired resistance mechanisms to EGFR-TKIs. Earlier studies suggested that tumor T790M could also be detected in TKI-naïve EGFR-mutated NSCLC. The aim of the study is to assess the prevalence and clinical significance of quantification of tumor pre-treatment T790M subclones.

more information